---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056286"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:12:09.099977+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Intellia Q1 net loss $107M; cash $953M; Phase 3 enrollment ahead; FDA alignment on ATTRv-PN trial

## Summary
- Net loss of $107.4M for Q1 2024; collaboration revenue $28.9M (up from $12.6M YoY) on $21M non-cash adjustment.
- Cash and marketable securities $953.4M as of Mar 31, 2024; expected to fund operations into late 2026.
- Phase 3 MAGNITUDE trial for ATTR-CM enrolling ahead of projections; over 30 patients dosed, 40+ in screening.
- FDA alignment on pivotal Phase 3 design for NTLA-2001 in ATTRv-PN; study of ~50 patients to initiate by year-end.
- On track to initiate NTLA-2002 Phase 3 for HAE in H2 2024; Phase 1 long-term data at EAACI June 2.

## SEC filing metadata
- accession: 0000950170-24-056286
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000095017024056286/0000950170-24-056286-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000095017024056286/ntla-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056286
- JSON: https://secwatch.observer/filing/0000950170-24-056286.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056286.txt

## Key facts
- Earnings Releases
  Intellia Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 9, 2024, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000095017024056286/0000950170-24-056286-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.